253 related articles for article (PubMed ID: 18298480)
1. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia.
Christ-Crain M; Breidthardt T; Stolz D; Zobrist K; Bingisser R; Miedinger D; Leuppi J; Tamm M; Mueller B; Mueller C
J Intern Med; 2008 Aug; 264(2):166-76. PubMed ID: 18298480
[TBL] [Abstract][Full Text] [Related]
2. Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia.
Nowak A; Breidthardt T; Christ-Crain M; Bingisser R; Meune C; Tanglay Y; Heinisch C; Reiter M; Drexler B; Arenja N; Twerenbold R; Stolz D; Tamm M; Müller B; Müller C
Chest; 2012 Apr; 141(4):974-982. PubMed ID: 22135381
[TBL] [Abstract][Full Text] [Related]
3. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?
Pereira JM; Teixeira-Pinto A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
J Crit Care; 2013 Dec; 28(6):970-4. PubMed ID: 24216331
[TBL] [Abstract][Full Text] [Related]
4. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
[TBL] [Abstract][Full Text] [Related]
5. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.
Krüger S; Ewig S; Marre R; Papassotiriou J; Richter K; von Baum H; Suttorp N; Welte T;
Eur Respir J; 2008 Feb; 31(2):349-55. PubMed ID: 17959641
[TBL] [Abstract][Full Text] [Related]
6. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections.
Müller B; Süess E; Schuetz P; Müller C; Bingisser R; Bergmann A; Stolz D; Tamm M; Morgenthaler NG; Christ-Crain M
J Intern Med; 2006 Dec; 260(6):568-76. PubMed ID: 17116008
[TBL] [Abstract][Full Text] [Related]
7. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD.
Stolz D; Breidthardt T; Christ-Crain M; Bingisser R; Miedinger D; Leuppi J; Mueller B; Tamm M; Mueller C
Chest; 2008 May; 133(5):1088-94. PubMed ID: 18339792
[TBL] [Abstract][Full Text] [Related]
8. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.
Müller B; Harbarth S; Stolz D; Bingisser R; Mueller C; Leuppi J; Nusbaumer C; Tamm M; Christ-Crain M
BMC Infect Dis; 2007 Mar; 7():10. PubMed ID: 17335562
[TBL] [Abstract][Full Text] [Related]
10. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic and stratified value of adrenomedullin in community acquired pneumonia patients in emergency department].
Chen Y; Li C
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Feb; 26(2):115-9. PubMed ID: 24524403
[TBL] [Abstract][Full Text] [Related]
12. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia.
Zhydkov A; Christ-Crain M; Thomann R; Hoess C; Henzen C; Werner Z; Mueller B; Schuetz P;
Clin Chem Lab Med; 2015 Mar; 53(4):559-66. PubMed ID: 25014522
[TBL] [Abstract][Full Text] [Related]
13. B-type natriuretic peptide in predicting the severity of community-acquired pneumonia.
Li J; Ye H; Zhao L
World J Emerg Med; 2015; 6(2):131-6. PubMed ID: 26056544
[TBL] [Abstract][Full Text] [Related]
14. Risk stratification and prediction value of procalcitonin and clinical severity scores for community-acquired pneumonia in ED.
Zhou H; Guo S; Lan T; Ma S; Zhang F; Zhao Z
Am J Emerg Med; 2018 Dec; 36(12):2155-2160. PubMed ID: 29691103
[TBL] [Abstract][Full Text] [Related]
15. The value of procalcitonin level in community-acquired pneumonia in the ED.
Park JH; Wee JH; Choi SP; Oh SH
Am J Emerg Med; 2012 Sep; 30(7):1248-54. PubMed ID: 22030193
[TBL] [Abstract][Full Text] [Related]
16. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
Bello S; Fandos S; Lasierra AB; Mincholé E; Panadero C; Simon AL; Gavin O; De Pablo F; Menendez R; Torres A
Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
[TBL] [Abstract][Full Text] [Related]
17. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia.
Christ-Crain M; Stolz D; Jutla S; Couppis O; Müller C; Bingisser R; Schuetz P; Tamm M; Edwards R; Müller B; Grossman AB
Am J Respir Crit Care Med; 2007 Nov; 176(9):913-20. PubMed ID: 17702966
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia.
Menéndez R; Martínez R; Reyes S; Mensa J; Filella X; Marcos MA; Martínez A; Esquinas C; Ramirez P; Torres A
Thorax; 2009 Jul; 64(7):587-91. PubMed ID: 19131448
[TBL] [Abstract][Full Text] [Related]
19. Mortality prediction using serum biomarkers and various clinical risk scales in community-acquired pneumonia.
Kim MW; Lim JY; Oh SH
Scand J Clin Lab Invest; 2017 Nov; 77(7):486-492. PubMed ID: 28678546
[TBL] [Abstract][Full Text] [Related]
20. Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from the B-type natriuretic peptide for acute shortness of breath evaluation study.
Christ M; Laule-Kilian K; Hochholzer W; Klima T; Breidthardt T; Perruchoud AP; Mueller C
J Am Coll Cardiol; 2006 Nov; 48(9):1808-12. PubMed ID: 17084254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
